Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 14/20 | 0.45 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.41 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543036 | 0.92 | GRIN2B (0.42) | GRIN2BTRPC3TRPC7CYP2D6CYP2C9 | |
| SCHEMBL15163576 | 0.92 | GRIN2B (0.43) | GRIN2BTRPC3TRPC7CYP2D6CYP2C9 | |
| SCHEMBL5547046 | 0.86 | GSK3B (0.42) | GSK3BL3MBTL1 | |
| SCHEMBL5545904 | 0.82 | BRD4 (0.42) | GRIN2BP2RX3GSK3BL3MBTL1 | |
| SCHEMBL5545522 | 0.77 | RXFP1 (0.41) | CYP2D6CYP2C9CYP3A4RAB9ASMN1; SMN2 | |
| SCHEMBL5540750 | 0.77 | L3MBTL1 (0.41) | GSK3BL3MBTL1 | |
| SCHEMBL5546984 | 0.76 | CNR2 (0.41) | GRIN2BGSK3BL3MBTL1 | |
| SCHEMBL15163638 | 0.76 | CNR2 (0.41) | GSK3BL3MBTL1 | |
| SCHEMBL5545482 | 0.76 | GRIN2B (0.42) | GRIN2BL3MBTL1 | |
| SCHEMBL5545334 | 0.75 | L3MBTL1 (0.42) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | BCDIN3D, DUT, SAMHD1 | GRIN2B 1400/4885TRPC3 3757/4885TRPC7 3996/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | GRIN2B 4036/4885TRPC3 4565/4885TRPC7 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.